| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Paul Enck | Q7150501 |
| Irene Lenoir-Wijnkoop | Q63253367 | ||
| Dirk Haller | Q30011791 | ||
| Stig B.S. Bengmark | Q54250285 | ||
| P2093 | author name string | Ger T Rijkers | |
| Jean-Michel Antoine | |||
| P2860 | cites work | Randomized controlled treatment trial of irritable bowel syndrome with a probiotic E.-coli preparation (DSM17252) compared to placebo. | Q54409689 |
| Inflammatory bowel disease in a Swedish twin cohort: a long-term follow-up of concordance and clinical characteristics. | Q55036605 | ||
| A mixture ofEscherichia coli(DSM 17252) andEnterococcus faecalis(DSM 16440) for treatment of the irritable bowel syndrome - A randomized controlled trial with primary care physicians | Q56883300 | ||
| Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease | Q57606857 | ||
| Association between a complex insertion/deletion polymorphism in NOD1 (CARD4) and susceptibility to inflammatory bowel disease | Q58200922 | ||
| VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis | Q59120549 | ||
| High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn’s disease | Q22250942 | ||
| Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis | Q22251072 | ||
| A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease | Q22251291 | ||
| Probiotic effects on intestinal fermentation patterns in patients with irritable bowel syndrome | Q24655815 | ||
| Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial | Q24685494 | ||
| Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine | Q24685766 | ||
| Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease | Q27860821 | ||
| Saccharomyces boulardii in maintenance treatment of Crohn's disease | Q28144634 | ||
| Functional variants of OCTN cation transporter genes are associated with Crohn disease | Q28258410 | ||
| Genetic variation in DLG5 is associated with inflammatory bowel disease | Q28258422 | ||
| A genome-wide association study identifies IL23R as an inflammatory bowel disease gene | Q28270603 | ||
| A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1 | Q29614873 | ||
| Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences | Q29617565 | ||
| Functional bowel disorders | Q29620328 | ||
| The primary defect in experimental ileitis originates from a nonhematopoietic source | Q30439653 | ||
| Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. | Q30581062 | ||
| Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis. | Q33231186 | ||
| Gastric distension and duodenal lipid infusion modulate intestinal gas transit and tolerance in humans | Q33425878 | ||
| The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome--a double blind, placebo-controlled, randomized study | Q33433775 | ||
| Prescript-Assist probiotic-prebiotic treatment for irritable bowel syndrome: a methodologically oriented, 2-week, randomized, placebo-controlled, double-blind clinical study | Q33433906 | ||
| A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating | Q33434046 | ||
| Review article: probiotics and prebiotics in irritable bowel syndrome | Q33440014 | ||
| Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial | Q33872486 | ||
| MDR1 Ala893 polymorphism is associated with inflammatory bowel disease | Q33905302 | ||
| A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome | Q33955996 | ||
| A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome | Q34010853 | ||
| The immunological and genetic basis of inflammatory bowel disease | Q34216426 | ||
| Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn's disease | Q34459129 | ||
| Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial | Q34510060 | ||
| Probiotics and Crohn's disease | Q34528530 | ||
| A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease | Q34560319 | ||
| A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease | Q34588311 | ||
| Guidelines on the irritable bowel syndrome: mechanisms and practical management. | Q34626602 | ||
| A probiotic treatment containing Lactobacillus, Bifidobacterium and Enterococcus improves IBS symptoms in an open label trial | Q35166841 | ||
| T cell specificity and cross reactivity towards enterobacteria, bacteroides, bifidobacterium, and antigens from resident intestinal flora in humans | Q35355393 | ||
| Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis | Q35596222 | ||
| Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis | Q35596664 | ||
| Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. | Q35760489 | ||
| Clinical relevance of advances in genetics and pharmacogenetics of IBD. | Q35787426 | ||
| Use of diet and probiotic therapy in the irritable bowel syndrome: analysis of the literature | Q36083884 | ||
| Design of treatment trials for functional gastrointestinal disorders | Q36470118 | ||
| Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date. | Q36735647 | ||
| Prebiotics, probiotics, and dietary fiber in gastrointestinal disease | Q36808253 | ||
| Bacteria- and host-derived mechanisms to control intestinal epithelial cell homeostasis: implications for chronic inflammation | Q36809889 | ||
| Meta-analysis of probiotics for the treatment of irritable bowel syndrome | Q37156630 | ||
| Clinical trial on the efficacy of a new symbiotic formulation, Flortec, in patients with irritable bowel syndrome: a multicenter, randomized study | Q39316115 | ||
| Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome | Q39348241 | ||
| A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome | Q39396709 | ||
| Increased intestinal permeability precedes the onset of Crohn's disease in a subject with familial risk | Q40735088 | ||
| Prescript-assist probiotic-prebiotic treatment for irritable bowel syndrome: an open-label, partially controlled, 1-year extension of a previously published controlled clinical trial | Q42628764 | ||
| Recent trends in the epidemiology of inflammatory bowel diseases: up or down? | Q42726365 | ||
| Effects of probiotic on intestinal mucosa of patients with ulcerative colitis | Q43159889 | ||
| High-dose probiotics for the treatment of active pouchitis | Q43353488 | ||
| Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial | Q43363077 | ||
| Mucosal flora in inflammatory bowel disease | Q43503928 | ||
| Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis | Q43867015 | ||
| Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome | Q44229588 | ||
| Failure to induce oral tolerance to a soluble protein in patients with inflammatory bowel disease | Q45024532 | ||
| Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis | Q45166043 | ||
| Single-blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome | Q45197036 | ||
| Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. | Q45826312 | ||
| Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome | Q46451586 | ||
| Crohn's disease is associated with a toll-like receptor-9 polymorphism | Q47243561 | ||
| Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. | Q53184076 | ||
| Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. | Q54198574 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | inflammatory bowel diseases | Q917447 |
| probiotics | Q1816730 | ||
| inflammation | Q101991 | ||
| P304 | page(s) | 690S-7S | |
| P577 | publication date | 2010-01-27 | |
| P1433 | published in | Journal of Nutrition | Q3186931 |
| P1476 | title | Guidance for substantiating the evidence for beneficial effects of probiotics: probiotics in chronic inflammatory bowel disease and the functional disorder irritable bowel syndrome | |
| P478 | volume | 140 |
| Q36699182 | Actual concept of "probiotics": is it more functional to science or business? |
| Q36012463 | Alterations in fecal microbiota composition by probiotic supplementation in healthy adults: a systematic review of randomized controlled trials |
| Q44967584 | Amelioration of DSS-induced murine colitis by VSL#3 supplementation is primarily associated with changes in ileal microbiota composition |
| Q26777641 | Antioxidant therapy for treatment of inflammatory bowel disease: Does it work? |
| Q38084051 | Challenges in translational research on probiotic lactobacilli: from in vitro assays to clinical trials |
| Q34883210 | Current and emerging drugs for the treatment of inflammatory bowel disease |
| Q34626740 | Differential Toll-like receptor recognition and induction of cytokine profile by Bifidobacterium breve and Lactobacillus strains of probiotics. |
| Q64998445 | Effect of Lactobacillus gasseri BNR17 on irritable bowel syndrome: a randomized, double-blind, placebo-controlled, dose-finding trial. |
| Q37072738 | Effect of type of TAG fatty acids on lutein and zeaxanthin bioavailability |
| Q37828084 | Health benefits of probiotics: are mixtures more effective than single strains? |
| Q35771429 | Hsp10, Hsp70, and Hsp90 immunohistochemical levels change in ulcerative colitis after therapy |
| Q28743610 | Identification and characterisation of an iron-responsive candidate probiotic |
| Q37905185 | Impact of maternal supplementation with probiotics during pregnancy on atopic eczema in childhood--a meta-analysis |
| Q21263105 | Indication for Co-evolution of Lactobacillus johnsonii with its hosts |
| Q36555442 | Integrative medicine and human health - the role of pre-, pro- and synbiotics |
| Q34664102 | Intestinal microbiota and blue baby syndrome: probiotic therapy for term neonates with cyanotic congenital heart disease |
| Q44660774 | Lactobacillus acidophilus La5 and Bifidobacterium lactis Bb12 induce different age-related metabolic profiles revealed by 1H-NMR spectroscopy in urine and feces of mice. |
| Q35148077 | Lactobacillus amylovorus inhibits the TLR4 inflammatory signaling triggered by enterotoxigenic Escherichia coli via modulation of the negative regulators and involvement of TLR2 in intestinal Caco-2 cells and pig explants |
| Q54637805 | Lactobacillus plantarum consumption increases PepT1-mediated amino acid absorption by enhancing protein kinase C activity in spontaneously colitic mice |
| Q52605186 | Lactobacillus plantarum surface layer adhesive protein protects intestinal epithelial cells against tight junction injury induced by enteropathogenic Escherichia coli |
| Q39370979 | Monitoring immune modulation by nutrition in the general population: identifying and substantiating effects on human health. |
| Q39458419 | Pathomechanisms of Oxidative Stress in Inflammatory Bowel Disease and Potential Antioxidant Therapies. |
| Q35271907 | Predominant effect of host genetics on levels of Lactobacillus johnsonii bacteria in the mouse gut. |
| Q46083282 | Probiotics can alleviate cardiopulmonary bypass-induced intestinal mucosa damage in rats |
| Q35637895 | Probiotics: The scientific evidence in the context of inflammatory bowel disease |
| Q98892417 | Regulation of the intestinal microbiota: An emerging therapeutic strategy for inflammatory bowel disease |
| Q37053638 | Role of commensal and probiotic bacteria in human health: a focus on inflammatory bowel disease |
| Q37936393 | Role of the microbiota in inflammatory bowel diseases |
| Q35800667 | Scientific evidence for health effects attributed to the consumption of probiotics and prebiotics: an update for current perspectives and future challenges. |
| Q33904884 | Spontaneous remission of Crohn's disease following a febrile infection: case report and literature review. |
| Q34647736 | Test-based exclusion diets in gastro-esophageal reflux disease patients: a randomized controlled pilot trial |
| Q48124178 | The TRPV1 channel in rodents is a major target for antinociceptive effect of the probiotic Lactobacillus reuteri DSM 17938. |
| Q46343224 | The potential synergistic behaviour of inter- and intra-genus probiotic combinations in the pattern and rate of short chain fatty acids formation during fibre fermentation. |
| Q38055197 | Two faces of microbiota in inflammatory and autoimmune diseases: triggers and drugs |
| Q44887797 | VSL#3 probiotics exerts the anti-inflammatory activity via PI3k/Akt and NF-κB pathway in rat model of DSS-induced colitis |
| Q36405806 | Vitamin D associates with improved quality of life in participants with irritable bowel syndrome: outcomes from a pilot trial |
Search more.